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Co-colonisation with Aspergillus fumigatus
and Pseudomonas aeruginosa is associated
with poorer health in cystic fibrosis
patients: an Irish registry analysis
Emma Reece1, Ricardo Segurado2, Abaigeal Jackson3, Siobhán McClean4,5, Julie Renwick1*

and Peter Greally3,6

Abstract
Background: Pulmonary infection is the main cause of death in cystic fibrosis (CF). Aspergillus fumigatus (AF) and
Pseudomonas aeruginosa (PA) are the most prevalent fungal and bacterial pathogens isolated from the CF airway,
respectively. Our aim was to determine the effect of different colonisation profiles of AF and PA on the clinical
status of patients with CF.
Methods: A retrospective analysis of data from the Cystic Fibrosis Registry of Ireland from 2013 was performed to
determine the effect of intermittent and persistent colonisation with AF or PA or co-colonisation with both
microorganisms on clinical outcome measures in patients with CF. Key outcomes measured included forced expiratory
volume in one second (FEV1), number of hospitalisations, respiratory exacerbations and antimicrobials prescribed, and
complications of CF, including CF related diabetes (CFRD) and allergic bronchopulmonary aspergillosis (ABPA).
Results: The prevalence of AF and PA colonisation were 11% (5% persistent, 6% intermittent) and 31% (19% persistent,
12% intermittent) in the Irish CF population, respectively. Co-colonisation with both pathogens was associated with a
13.8% reduction in FEV1 (p = 0.016), higher levels of exacerbations (p = 0.042), hospitalisations (p = 0.023) and
antimicrobial usage (p = 0.014) compared to non-colonised patients and these clinical outcomes were comparable to
those persistently colonised with PA. Intermittent and persistent AF colonisation were not associated with poorer
clinical outcomes or ABPA. Patients with persistent PA had a higher prevalence of CFRD diagnosis (p = 0.012).
Conclusions: CF patients co-colonised with AF and PA had poor clinical outcomes comparable to patients persistently
colonised with PA, emphasising the clinical significance of co-colonisation with these microorganisms.
Keywords: Co-colonisation, Cystic Fibrosis, Aspergillus fumigatus, Pseudomonas aeruginosa, Pulmonary function

Background
Cystic fibrosis (CF) is the most common inherited life
shortening condition affecting Caucasians. It is estimated
that there are over 70,000 people living with CF worldwide [1]. It is a multi-organ disease however up to 95%
of morbidity and mortality is caused by airway infections
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and the associated inflammation [2]. Mutations in the
CF transmembrane conductance regulator (CFTR) gene
result in dysfunctional or absent CFTR protein which ultimately results in thick airway mucus and impaired
mucocilliary clearance. This provides the perfect environment for microorganisms to colonise and persist. The
path of disease progression is established early in life
with deterioration in lung function beginning as early as
age 6 [3]. The recurrent onslaught of airway infection
and inflammation results in reduced lung function and
eventually respiratory failure.
Airway infection management is the cornerstone of CF
care and it is now widely accepted that the CF airways
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are colonised with a community of microorganisms from
an early age [2–4]. Microorganisms previously not considered to be significant in CF microbiology are emerging as having roles in disease progression [4, 5]. The
discovery of complex and diverse microbial communities
in the airways is forcing a paradigm shift in the treatment
of airway infections. Considering this, research into coinfections and polymicrobial infections is imminent. Here
we aimed to determine the clinical implications of coinfection with the most common fungal and bacterial
pathogen isolated from the CF airways.
Aspergillus fumigatus (AF) is the most common fungal
pathogen isolated from the CF airways with a reported
prevalence between 16 and 58% [6–10]. AF rarely causes
invasive infections in CF however it can cause allergic
bronchopulmonary aspergillosis (ABPA), a hypersensitivity
reaction to AF with detrimental consequences on airway
inflammation. Generally intermittent or persistent AF colonisation is not treated unless ABPA is confirmed. Criteria
for diagnosis of ABPA are based on the CF Foundation
consensus [10]. At present there is no consensus for the
diagnosis or treatment of asymptomatic AF colonisation in
CF. Recent studies have utilized a combination of AF
qPCR, galactomannan, AF specific IgE and IgG to decipher
the complexity of AF colonisation status in CF patients.
Classifying patients into proposed subgroups and delineating those with ABPA from those who are AF sensitised, AF non-sensitised and those with aspergillus
bronchitis [11]. Some studies have provided valuable insights into how AF may influence the progression of CF
lung disease [9, 12, 13] however the true extent of the
impact on disease progression is unknown.
Pseudomonas aeruginosa (PA) is the most common
bacterial pathogen in CF [14] and in 2013, the Cystic Fibrosis Foundation in the US reported 48.7% of patients
were colonised with PA [15]. Early PA colonisation of
the CF airway is frequently intermittent and eradication
is possible using inhaled antibiotics. However recolonisation can occur and in some cases despite intense
efforts to re-eradicate the organism, the colonisation becomes persistent and a decline in lung function ensues
[16, 17]. The transition from intermittent to chronic or
persistent PA colonisation is a seminal clinical event in a
CF patient’s life and persistent PA colonisation is associated with increased mortality [18, 19].
Despite substantial improvement in median survival,
CF remains a life-shortening disease with the mean age
of death in Ireland being only 22.8 years [20] and pulmonary insufficiency is the main cause of death. There is
a paucity of published data on the prevalence of persistent AF colonisation or AF and PA co-colonisation in CF
patients. We aimed to determine the prevalence of persistent and intermittent colonisation with PA or AF and
co-colonisation with both pathogens in the Irish CF
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population. Furthermore we aimed to determine the association of these different colonisation patterns with
the clinical status of patients with CF.

Methods
Study population

Data from patients with CF registered in the Cystic Fibrosis Registry of Ireland (CFRI) database in 2013 was used in
this study. The number of live patients registered with the
CFRI was 1158 on the last day of 2013 (92.5% of the Irish
CF population) and data from 749 patients was included
in this study (409 patients with incomplete data sets were
excluded). A retrospective cohort study was carried out to
establish whether colonisation with AF and/or PA impacts
on patient health. The primary clinical outcome measure
was forced expiratory volume in one second percent predicted (FEV1%) and secondary clinical outcome measures
were the number of hospitalisations, respiratory exacerbations (treated with intravenous antibiotics), prescribed antimicrobials and complications of CF, including pancreatic
insufficiency resulting in CFRD and ABPA. CFRD diagnosis was defined as being treated with insulin for CF-related
diabetes, ABPA diagnosis was reported by the physician.
Sputum (n = 1859), throat swabs (n = 31), cough swabs
(n = 52), nasal swab (n = 1) and bronchoalveolar lavage
(n = 10) samples were recorded as positive for PA and/or
AF by the individual hospitals. We employed stringent
criteria to classify colonisation status: greater than 2 but
less than 4 respiratory samples positive within the year
was considered intermittent colonisation and greater
than 4 samples positive within the year was considered
persistent colonisation, in line with the Leeds criteria
[21]. Patients were separated into 6 cohorts depending on
their colonisation status: 1) intermittent PA colonisation
(PA), 2) persistent PA colonisation (PAp), 3) intermittent
AF colonisation (AF), 4) persistent AF colonisation
(AFp), 5) colonised with both pathogens (AF + PA) and
6) negative for both pathogens (clear). Clinical outcome
measures were compared between our six cohorts.
Statistical analysis

D’Agostino and Pearson omnibus normality test was performed on FEV1% predicted data. FEV1 data was not normally distributed and outcomes comparisons between
groups were made using the Kruskal-Wallis test with
Dunn’s multiple comparisons. In order to adjust for the
potential confounders: age, gender and CFTR mutation,
linear regression was used for FEV1% predicted and logistic regression models were used for steroid use,
ABPA and CFRD positivity yielding Odds Ratios (ORs)
for the “poorer” outcomes.
The number of hospitalisations, respiratory exacerbations and the number of antimicrobials were modelled with
a Poisson or Negative Binomial regression. The degree of
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zero-inflation and over dispersion was assessed by comparing the model Pearson statistic to the sample size for each
outcome. In all cases a zero-inflated Negative Binomial
model (ZINB) provided the best-fit model yielding Incident
Rate Ratios (IRRs). Following this analysis, post hoc tests
of all pair-wise comparisons were conducted using a
Bonferroni correction for 6 tests (Bonferroni adjusted
p-value = 6 × p-value), and Bonferroni-adjusted 95%
confidence intervals (99.583% confidence required).
Significance level was assumed at below 0.05. Analyses
were conducted in IBM SPSS Statistics version 20 and
SAS for Windows version 9.3. Detailed description of
data analysis protocols is provided in Additional file 1.
All p values shown are after adjustment for age, sex
and CFTR mutation unless otherwise stated.

Results and Discussion
Demographics of the patient population

The male cohort made up the bigger subset of the CF
population at 58.6%, reflecting higher mortality rates in
females in adolescence and early adulthood [22]. The
age distribution in our dataset was 4–69 years and the
median age was 18.1 years. The demographic and clinical
data of the cohorts are depicted in Table 1. As expected
the FEV1 percent predicted was lower in older patients
reflecting a gradual decline with age (Fig. 1).
Prevalence of AF and PA colonisation in the Irish CF
population

The prevalence of AF and PA co-colonisation was 3.1%
in the Irish CF population. The AF + PA group included
AFp + PA (n = 4), AF + PA (n = 5), AF + PAp (n = 7) and
AFp + Pap (n = 8) subgroups. No significant differences
in FEV1, number of hospitalisations, number of respiratory
exacerbations and antimicrobial prescribing were noted between these subgroups (Additional file 2: Table S1). AF colonisation was most prevalent in pre-adolescents and
adolescents (Fig. 1), which contradicts current opinion that
AF is more commonly an organism encountered in adulthood. To our knowledge this has not been previously reported. The prevalence of AF colonisation in the Irish CF
population was 11%, of which 5% had persistent and 6%

intermittent colonisation (Table 1). Previously AF prevalence rates in CF have been reported to be up to 58% using
sputum culture [8]. PA becomes more prevalent with age
and FEV1 decline, corroborating previous findings (Fig. 1)
[23]. The prevalence of PA in the Irish CF population was
31%, of which 19% had persistent and 12% had intermittent colonisation (Table 1). The prevalence of PA colonisation in Ireland is lower than the 48.7% prevalence reported
in the US [17]. Employing similar criteria for the classification of persistent and intermittent PA colonisation as our
study, Lee et al., (2003) [21] determined the prevalence of
persistent PA to be 18% consistent with our data and intermittent colonisation to be 34%, which is higher than our
findings. Proesmans et al., (2006) [24] determined the
prevalence of persistent and intermittent PA colonisation
to be 31 and 18% respectively which are higher than our
prevalence rates. Many of these studies differ in the criteria
employed for categorising colonisation status making comparisons between them difficult. We employed stringent
criteria to classify colonisation status in line with the Leed’s
criteria [21] as outlined in our methods. The Leed’s criteria
have been independently evaluated [24] and are the classification criteria recommended in the European CF Society
patient registry guidelines [25]. We did not consider positivity of AF and PA in one sputum sample in a year as
intermittent, as other studies have done [6–8, 26], to rule
out inclusion of chance events, false positives or sputum
contamination. For these reasons our prevalence for AF
and PA colonisation may be lower than reported elsewhere
[6–9, 15, 21, 24, 26]. Consensus criteria for the definition
of intermittent and persistent AF colonisation, comparable
to the Leeds criteria for PA, need to be formulated. We acknowledge that a limitation of this study is its crosssectional design and multi-year analysis of registry data
would provide further detail on transition from intermittent to persistent colonisation status and the impact on
disease outcome measures.
Persistent colonisation with PA or co-colonisation with AF
was associated with reduced lung function

Patients co-colonised with both AF and PA had an FEV1
13.8% lower than non-colonised patients (p = 0.016)

Table 1 Demographic and clinical data of the study cohorts
PA

PAp

AF

AFp

AF + PA

Clear

82 (10.9%)

130 (17.4%)

36 (4.8%)

26 (3.5%)

23 (3.1%)

452 (60.3%)

Median Age (range)

26 (7–69)

25 (6–48)

15 (6–36)

15 (5–29)

20 (9–45)

14 (4–56)

CFTR Genotype

phe508del/phe508del

6.8%

10.3%

2.8%

2.9%

1.7%

30.8%

phe508del/other

3.8%

6%

1.6%

0.4%

1.1%

24.3%

other

0.5%

0.8%

0.27%

0.13%

0.27%

4%

unknown

0.13%

0.27%

0.13%

0%

0%

1.2%

21.2a (13.1–34.9)

20 (9–30.2)

19 (14.3–26.8)

18.7 (14.3–26.1)

19 (12.3–25.7)

18.9 (10.4–33.7)

Number (%)

Median BMI (range)
a

indicates missing data

Reece et al. BMC Pulmonary Medicine (2017) 17:70

Page 4 of 8

Fig. 1 Average FEV1 % predicted and prevalence of PA and AF colonisation in patients stratified by age. Error bars represent standard error of the mean

(Fig. 2) and co-colonised patients had comparable reductions in lung function to patients persistently colonised
with PA. Consistent with our data, Amin et al., (2010)
[9] reported that persistent infection with both AF and
PA was associated with lower lung function. The transition of PA colonisation from intermittent to persistent is
a disease milestone that cannot be reversed and is associated with worse prognosis [18, 27]. We have shown
that patients co-colonised with PA and AF had similar
reductions in lung function as patients with persistent PA.
This is the first time this has been reported. In a recent
longitudinal study the sputum microbiology and clinical
outcomes of 770 adolescents with CF were recorded and
AF was the only species that was associated with an increased risk for infection with PA [28]. This highlights the
importance of monitoring the co-colonisation status of CF
patients. Perhaps AF colonisation establishes a milieu that
enables PA to become persistent and attention to AF during this phase may prevent progression to persistent PA.
Further data is required to explore this hypothesis.
Patients with persistent PA colonisation had an FEV1
11.9% lower than patients who were intermittently colonised with PA (unadjusted p = 0.0074), which remained
significant following adjustment for confounding factors
(p < 0.001) (Fig. 2). Previously intermittent PA colonisation
has been associated with lower FEV1 [21] (when adjusted
for age and gender only). Following data adjustment for
confounding factors (age, gender and CFTR mutation) the
FEV1 of patients intermittently colonised with PA were
not significantly different from the FEV1 of non-colonised
patients. Persistent PA colonisation negatively impacted

on lung function in agreement with others [21, 23]. Early
onset PA colonisation can be eradicated in over 90% of
colonised patients by antibiotic therapy [29], therefore
efforts should be targeted towards early detection of PA
colonisation and preventing establishment of persistent
colonisation. Interestingly 2 studies have now shown
that polymerase chain reaction methods can detect PA
4.5 months [30] to 8 months [31] in advance of current
culture-based techniques used commonly in diagnostic

Fig. 2 Average FEV1 percent predicted in the six colonisation cohorts.
Average FEV1% predicted for patients with no PA or AF colonisation
(Clear), intermittent AF colonisation (AF), persistent AF colonisation
(AFp), intermittent PA colonisation (PA), persistent PA colonisation (PAp)
and both AF and PA co-colonisation (AF + PA). Error bars represent min
and max values. Asterisks refer to comparison with Clear, unless over a
horizontal bar, ** p ≤ 0.01, *** p ≤ 0.001 (adjusted data). ∞ indicates
significance only prior to data adjustment
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laboratories. This provides evidence to support the use of
molecular-based methods for superior detection of PA.
Patients with intermittent and persistent AF colonisation had 4 and 11% lower FEV1, respectively, than noncolonised patients however these were not statistically
significant. A previous study showed patients with AF
sensitisation or persistent carriage had 16.5% lower FEV1
than the control group [32]. Amin et al., (2010) [9]
showed that patients persistently colonised with AF had
a 3.6% decrease in FEV1 compared to patients who were
clear of AF, however when the data was adjusted for
baseline pulmonary function, this decrease was not significant. In agreement with our data, other studies suggest no correlation between AF colonisation and a
decline in pulmonary function [33, 34].
Persistent colonisation with PA or co-colonisation with
both PA and AF was associated with more frequent
hospitalisations, more respiratory exacerbations and
higher use of antimicrobials

For the first time we have shown that being culture positive for both AF and PA is associated with similar levels
of hospital admissions, exacerbations and antimicrobial
prescribing as being persistently colonised with PA
(Table 2). Patients co-colonised with both AF and PA
had a 165% increase in hospital admissions per person
(p = 0.023), a 112% increase in the number of respiratory
exacerbations per person (p = 0.042) and 48% increase in
antimicrobial prescribing (p = 0.009) when compared to
patients who were clear of both pathogens (Table 2).
Co-colonised patients had a 64% increase in respiratory
exacerbations compared to patients intermittently colonised with PA (p = 0.015) (Table 2).
Patients persistently colonised with PA had an 89% increase in the number of hospital admissions per person

within the year (p = 0.004), a 91% increase in respiratory
exacerbations (p < 0.001) and a 55% increase in antimicrobial prescribing (p < 0.001) compared to noncolonised patients (Table 2). In comparison to intermittently colonised patients, those persistently colonised
with PA had a 60% increase in the number of exacerbations (p = 0.001) and 23% increase in antibiotic prescribing (p = 0.014) (Table 2). There was no increase in the
number of hospitalisations, respiratory exacerbations or
antimicrobial prescribing in patients who were intermittently colonised with PA compared to non-colonised
patients.
Patients intermittently or persistently colonised with AF
showed no increase in the number of hospitalisations or respiratory exacerbations per person compared to noncolonised patients. However intermittently and persistently
colonised patients had a 63% and 90% increase in antimicrobial prescribing compared to non-colonised patients
(p = <0.001 and p = 0.001 respectively) (Table 2). The prevalence of Aspergillus sp was previously shown to be higher
in CF patients receiving prophylactic antibiotic therapy [33]
and we also observed an association between AF colonisation and antimicrobial prescribing. We speculate that this
finding may reflect antimicrobial suppression of bacteria facilitating fungal growth. It is also possible that AF colonisation establishes a milieu suitable for bacterial colonisation,
which would impact on antimicrobial prescribing. No differences were observed between the cohorts regarding inhaled steroid use, steroids taken daily and steroids taken
alternative days (Additional file 3: Figure S1).
Patients colonised with PA had a higher prevalence of
CFRD

A total of 14.7% of patients with CF had diabetes requiring insulin in 2013. Patients persistently colonised with

Table 2 Incident Rate Ratio (IRR) of the incidence of hospitalisations, respiratory exacerbations and prescribed antimicrobials between
cohorts
Hospitalisations

Respiratory Exacerbations

Antimicrobials

Comparison

IRR (95% CI)

p value

IRR (95% CI)

p value

IRR (95% CI)

p-value

PA vs Clear

1.00 (0.44, 2.30)

1

0.76 (0.37, 1.55)

1

1.19 (0.93, 1.51)

0.259

PAp vs Clear

1.89 (1.11, 3.22)

0.004

1.91 (1.19, 3.05)

<0.001

1.55 (1.29, 1.86)

<0.001

AF vs Clear

1.16 (0.54, 2.48)

1

0.95 (0.45, 1.98)

1

1.63 (1.19, 2.21)

<0.001

AFp vs Clear

1.97 (0.75, 5.20)

0.271

1.59 (0.74, 3.44)

0.494

1.9 (1.38, 2.62)

<0.001

AF + PA vs Clear

2.65 (1.01, 6.97)

0.023

2.12 (0.95, 4.72)

0.042

1.48 (1.04, 2.11)

0.009

PA vs PAp

0.53 (0.23, 1.23)

0.189

0.4 (0.19, 0.81)

0.001

0.77 (0.60, 0.98)

0.014

AF vs Afp

0.59 (0.21, 1.67)

0.872

0.59 (0.24, 1.47)

0.775

0.86 (0.56, 1.30)

1

AF + PA vs PA

0.38 (0.12, 1.21)

0.099

0.36 (0.13, 0.95)

0.015

0.8 (0.54, 1.19)

0.668

AF + PA vs PAp

1.40 (0.53, 3.73)

1

1.11 (0.51, 2.43)

1

0.96 (0.66, 1.38)

1

AF + PA vs AF

0.45 (0.15, 1.33)

0.209

0.47 (0.17, 1.31)

0.205

1.09 (0.69, 1.74)

1

AF + PA vs AFp

1.30 (0.38, 4.44)

1

0.79 (0.28, 2.21)

1

0.78 (0.49, 1.25)

0.8

Italicized bold text highlights significance of <0.05.
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PA had a higher prevalence of CFRD diagnosis than
non-colonised patients (p = 0.012) (Additional file 4:
Table S2). A direct link between insulin deficiency and
clinical decline has been shown and patients with CFRD
were more likely to be persistently colonised with
Pseudomonas sp. [35].
AF colonisation was not associated with prevalence of
ABPA

The overall prevalence of ABPA was 5.9%. Patients cocolonised with AF and PA had the highest prevalence of
ABPA (17.4%) but this was not significantly higher than
the other groups (Additional file 4: Table S2). Interestingly, patients intermittently or persistently colonised
with AF showed no increased prevalence of ABPA. It is
not currently understood why some AF colonised patients are vulnerable to developing ABPA and others are
not. A number of single nucleotide polymorphisms
(SNPs) have been linked to susceptibility to ABPA. SNPs
in the IL-4 receptor alpha chain (IL-4Rα) gene [36], the
mannose-binding lectin (MBL) 2 gene [37, 38], the tolllike receptor 9 (TLR9) gene [39] and the pulmonary surfactant protein (SPA-2) gene [40] have been identified as
genetic risk factors for the development of ABPA. In
particular, SNPs in the promoter region of the IL-10
gene were found to be associated with Aspergillus colonisation and ABPA in patients with CF. Further studies in
the CF setting could yield interesting insights into the
susceptibility of CF patients to Aspergillus colonisation
and development of allergic disease. Culture of AF from
respiratory secretions of CF is only a secondary criterion
for the diagnosis of ABPA, due to the large number of
asymptomatically AF colonised CF patients. A retrospective study on 236 patients with CF found that 25%
of patients had positive AF culture results but of these
only 15 patients (6.5% of the total population) were
ABPA positive [41]. In parallel with our findings, positive
culture results for Aspergillus did not seem to represent
a specific risk factor for ABPA [40, 42].
The CF airways are colonised with a diverse community
of microorganisms from an early age [2–4]. Interactions
between the varieties of dominant and low abundance microorganisms in these communities are likely to impact
patient health. The most commonly isolated bacteria and
fungi from CF samples are PA and AF, respectively and we
have shown that co-colonisation with these two microorganisms is associated with poor clinical outcomes. Previous studies have shown that PA and AF are capable of
interacting and competing, which may have implications
on CF airway disease. Pyocyanin and 1-hydroxy-phenazine
produced by PA both have anti-AF activity [43] and PA
has been shown to inhibit AF biofilm formation by direct
cell contact and by excreted molecules [44, 45]. More recently the Pf4 bacteriophage produced by PA was shown
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to reduce both biofilm formation and pre-formed biofilms
of AF and this effect was linked to inhibition of AF metabolism via Pf4 iron sequestration [46]. AF has been
shown to enhance the production of PA elastase when
in co-culture and these co-culture supernatants were
more damaging to lung epithelial cell lines than PA supernatants alone [47]. We hypothesize that these PA-AF interactions may play a role in the damaging pathology
associated with CF airway disease and may explain why
patients who are co-colonised with PA and AF have a
poorer prognosis than those who are clear of both pathogens. Further studies on the interaction of these two microorganisms are warranted to expand our understanding
of how co-colonisation may impact the CF airways.

Conclusions
Persistent PA colonisation was associated with more respiratory exacerbations, more hospitalisations and lower
lung function than non-colonised patients. For the first
time we have shown that co-colonisation with AF and
PA resulted in comparable levels of hospitalisations, respiratory exacerbations and lung function reduction as
persistent PA colonisation. Patients with persistent PA
had a higher prevalence of CFRD diagnosis. Intermittent
and persistent AF colonisation was not associated with
poorer clinical outcomes or ABPA. This is a crosssectional registry analysis therefore a prospective longitudinal study is warranted to confirm these findings.
Additional files
Additional file 1: Supplementary Methods. Further details on the statistics
performed on this data (DOCX 140 kb)
Additional file 2: Table S1. Comparison of disease outcome measures
between the co-colonised sub-groups (PNG 74 kb)
Additional file 3: Figure S1. Percentage of patients prescribed steroids
in each cohort. Percentage of patients prescribed inhaled steroids, oral
steroids every day and oral steroids every alternative day for patients
within the 6 cohorts (PNG 109 kb)
Additional file 4: Table S2. Odds ratios are presented to determine the
odds of a particular colonisation status being linked to development of
CFRD and/ or ABPA. (PNG 75 kb)
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